Eli Lilly reported third‑quarter revenue that materially exceeded Street expectations and raised its full‑year outlook, driven by blockbuster performance from its diabetes and weight‑loss portfolio. The company also announced a $1.2 billion investment to build a Puerto Rico factory dedicated to an oral GLP‑1 candidate (orforglipron), signaling continued capacity expansion to meet surging demand. Lilly’s quarterly strength underscores the commercial power of GLP‑1 and dual‑agonist franchises; the factory move aims to secure oral dose production scale for future launches. Management framed the capital allocation as long‑term investment in manufacturing resilience and supply security amid rapid market growth. Investors and competitors will watch how Lilly balances manufacturing build‑out, pricing pressure and market access as oral and injectable GLP‑1 programs proliferate.